PubMed:10318905 / 938-1127
Annnotations
PMID_GLOBAL
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T11 | 40-43 | DiseaseOrPhenotypicFeature | denotes | MAP | 0012041 |
| T12 | 173-188 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T6 | 0-189 | Sentence | denotes | Furthermore, we found this HER2/Neu --> MAP kinase --> AR-ARAs --> PSA pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment of prostate cancer. |
| T6 | 0-189 | Sentence | denotes | Furthermore, we found this HER2/Neu --> MAP kinase --> AR-ARAs --> PSA pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment of prostate cancer. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T20 | 67-70 | gene:354 | denotes | PSA |
| T21 | 173-188 | disease:C0600139 | denotes | prostate cancer |
| T22 | 67-70 | gene:354 | denotes | PSA |
| T23 | 173-188 | disease:C0376358 | denotes | prostate cancer |
| R11 | T20 | T21 | associated_with | PSA,prostate cancer |
| R12 | T22 | T23 | associated_with | PSA,prostate cancer |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 173-188 | HP_0012125 | denotes | prostate cancer |
| T9 | 182-188 | HP_0002664 | denotes | cancer |